A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
A Phase III Study of ESG401 for Unresectable Recurrent or Metastatic Triple-Negative Breast Cancer	Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma	Recruiting	Phase 3	2025-09-23		NCT06732323

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Qilu Pharmaceutical Co., Ltd.	126

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Cancer Institute and Hospital, Chinese Academy of Medical Sciences	Beijing	China	16

Clinical trials